Inhibition of angiogenesis
AssigneeMorphotek, Inc.
InventorsDouglas B. Jacoby, Abdellah Sentissi, E. Michael Egan, Kamala Kesavan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel methods of inhibiting angiogenesis using chlorotoxin agents. In some embodiments, the inventive methods include intravenous, intraocular, intravitreal, subjunctival injection, and/or topical administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment and/or amelioration of ocular diseases characterized by neovascularization, such as wet macular degeneration. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
Claims2
A method of identifying agents that compete for binding to Annexin A2 with a chlorotoxin polypeptide comprising SEQ ID NO:
- 1, said method comprising:
- (a) providing a sample comprising cells that express Annexin A2;
- (b) contacting the sample with a test agent in the presence of said chlototoxin polypeptide;
- (c) determining whether binding of the test agent inhibits binding of said chlototoxin polypeptide to the cells that express Annexin A2;
- and
- (d) identifying the test agent as an agent that competes for binding to Annexin A2 with chlorotoxin if binding of the test agent inhibits binding of said chlototoxin polypeptide to the cells that express Annexin A2.
Dependencies are inferred from the claim text.